FAKTOR OPTIONSSCHEIN - MODERNA | Market Closed - BOERSE MUENCHEN 14:26:07 2024-06-21 EDT | ||
| 1.164 EUR | +0.09% |
|
| Current month | +11.92% | ||
| 1 month | -4.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 1.164 | +0.09% |
| 24-06-20 | 1.163 | -5.91% |
| 24-06-19 | 1.236 | +5.28% |
| 24-06-18 | 1.174 | +12.24% |
| 24-06-17 | 1.046 | -1.51% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 02:26 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Goldman Sachs |
| WKN | GK8RXA |
| ISIN | DE000GK8RXA8 |
| Date issued | 2022-08-05 |
| Strike | 179.2 $ |
| Maturity | Unlimited |
| Parity | 36.05 : 1 |
| Emission price | 10.27 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.06 € |
|---|---|
| Lowest since issue | 0.65 € |
| Spread | 0.01 € |
| Spread % | 0.83% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.4
USD
Average target price
145.9
USD
Spread / Average Target
+9.34%
- Stock Market
- Certificates
- Certificat
